Loading clinical trials...

Home Based Exercise for Patients With Breast or Prostate Cancer (The BENEFIT-CA Study) | Clinical Trials | Clareo Health

UNKNOWNNA

Home Based Exercise for Patients With Breast or Prostate Cancer (The BENEFIT-CA Study)

Home Based Exercise for Patients With Breast or Prostate Cancer During Treatment: a Feasibility Trial (The BENEFIT-CA Study)

NCT05258526•Hospital de Clinicas de Porto Alegre

View on ClinicalTrials.gov

Summary

The purpose of this trial is to evaluate the feasibility of a home based exercise program for individuals with breast or prostate cancer patients undergoing active treatment.

Detailed Description

This feasibility trial aims to assess a home-based exercise program, including a 3-month intervention of structured physical activity and health education for individuals with breast or prostate cancer. The main objective of this trial is to assess the adherence of cancer patients to a program of structured exercise, mixed with a health education approach, implemented and accompanied in a remote approach. The data collection will include variables related to: (a) recruitment and retentions rates; (b) attendance to exercise sessions; (c) fatigue and quality of life levels; (d) functional capacity levels; (e) adverse events related or not to the study; (f) patient selected outcomes.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•eighteen years old minimum;
•be living in Porto Alegre or metropolitan region;
•breast cancer stage 0 - III OR
•localized prostate cancer;
•undergoing hormonal treatment / manipulation in isolation or combined with other therapies three months prior to the entrance in the study;
•hormonal therapy / manipulation planned to be active throughout the study duration;
•not engaged in any exercise training for more than once a week for the past 6 months;
•in case of previous surgical procedure, the patient must have medical clearance at the moment of the contact to begin the study or be cleared to do so in the near future (up to two weeks).

Exclusion Criteria

•metastatic phase / progression of the disease or active regional location prior to beginning of the study;
•inability to understand the terms and conditions of study due to language, hearing, cognitive or severe psychiatric issues;
•another family member, who lives at the same residence, participating in the study;
•planning to move or major absence (more than two weeks) during the study;
•history of cardiovascular disease (except controlled hypertension) or severe cardiopulmonary disease, as well as history of heart attack, revascularization procedures, profound venous thrombosis, encephalic vascular accident (brain stroke) or pulmonary embolism in the past twelve months;
•chronic pulmonary disease that requires oxygen or corticosteroid therapy;
•kidney disease with or that is going to begin the use of dialysis or waiting for a kidney transplant;
•severe nausea, anorexia or any other condition which does not allow to perform physical exercise;
•medical contraindication to exercise training.

Locations (1)

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Key Dates

Start Date

April 7, 2022

Primary Completion Date

December 30, 2023

Completion Date

December 30, 2023

Last Updated

August 9, 2022

Enrollment

ESTIMATED participants

Conditions

Breast CancerProstate Cancer

Interventions

Home based exercise training

OTHER

Contacts

Daniel Umpierre de Moraes, PhD

CONTACT

555133596332 danielumpierre@hcpa.edu.br

Larissa Xavier Neves da Silva, Master

CONTACT

555133596332 larissaxns@gmail.com

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

RECRUITINGPHASE2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine Carcinoma+2 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 9, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Home Based Exercise for Patients With Breast or Prostate Cancer (The BENEFIT-CA Study)

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors